MedPage Today on MSN
New FDA-Approved Option for HER2-Mutated Lung Cancer
The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).
The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based ...
The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing ...
The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously treated locally advanced or metastatic, nonsquamous non–small cell lung cancer ...
The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with ...
MedPage Today on MSN
Triglyceride-Lowering Drug Gets FDA Nod for Rare Genetic Disorder
The small interfering RNA (siRNA) therapy, designed to reduce triglyceride levels by suppressing production of apolipoprotein ...
GlobalData on MSN
FDA approves AbbVie’s Epkinly to treat follicular lymphoma
The US FDA has granted approval for AbbVie’s Epkinly to treat adult patients with relapsed or refractory (R/R) follicular ...
The ANDROMEDA trial showed improved MOD-PFS and OS with daratumumab and hyaluronidase plus VCd compared to VCd alone in light ...
A recent analysis reveals that monthly prices of checkpoint inhibitors decreased only a small amount over a decade.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback